Nuformix plc (LON:NFX – Get Free Report)’s stock price was down 32.4% during mid-day trading on Wednesday . The stock traded as low as GBX 0.10 ($0.00) and last traded at GBX 0.10 ($0.00). Approximately 343,525,563 shares were traded during mid-day trading, an increase of 375% from the average daily volume of 72,272,914 shares. The stock had previously closed at GBX 0.15 ($0.00).
Nuformix Stock Down 29.7 %
The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The firm has a 50 day simple moving average of GBX 0.06 and a 200-day simple moving average of GBX 0.10. The stock has a market cap of £835,696.20, a P/E ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Basic Materials Stocks Investing
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Trading Stocks: RSI and Why it’s Useful
- What Does the Future Hold for Eli Lilly?
- Transportation Stocks Investing
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.